Isa-VRd for frail older adults with high-risk myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a combination of three drugs (isatuximab, bortezomib, lenalidomide, and a steroid) for people with newly diagnosed multiple myeloma who are older or frail and cannot have a stem cell transplant. It focuses on those with a certain type of myeloma cell in their blood, to see if the treatment works well and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are newly diagnosed with active multiple myeloma and have not had any treatment for it yet.
- Your blood test shows a specific type of myeloma cell (circulating plasma cells) that is 0.07% or more.
- You are not eligible for a stem cell transplant due to age, frailty, or other health issues.
- You are generally able to care for yourself (ECOG performance status 0 to 3).
- Your major organs (like heart, kidneys, liver) are working well enough to handle the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four drugs—isatuximab, bortezomib, lenalidomide, and dexamethasone—for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant. The goal is to see if adding isatuximab helps control the cancer better.
This trial tests a combination of drugs (isatuximab, bortezomib, lenalidomide, and dexamethasone) for people with newly diagnosed high-risk multiple myeloma who cannot or choose not to have a stem cell transplant. It aims to see if this treatment helps control the disease better.
This Phase 2 study tests whether “isa-Rd” can safely and effectively treat people who have newly diagnosed multiple myeloma and are frail or much older. It may help those who are at higher risk of side effects from stronger, full-intensity chemotherapy.
This study tests a combination of three drugs (isatuximab, dexamethasone, and lenalidomide) given at a slow, gentle pace for people with multiple myeloma who are considered very frail. The goal is to see if this gentler approach works well and is safe for those who may not tolerate stronger treatments.
This trial tests a combination of four drugs (daratumumab, bortezomib, lenalidomide, and dexamethasone) for people newly diagnosed with a high-risk form of multiple myeloma called double-hit myeloma. It aims to see if this drug combo can improve outcomes for those with two or more high-risk genetic changes.
This early-phase study compares two drug combinations—chidamide plus VRD versus VRD alone—to see which works better for primary high-risk multiple myeloma. The goal is to improve response while closely monitoring side effects and heart/lung safety.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.